HLS Therapeutics (OTCMKTS:HLTRF – Get Rating) had its price objective decreased by equities research analysts at Canaccord Genuity Group from C$30.50 to C$27.00 in a report issued on Thursday, The Fly reports. The brokerage presently has a “buy” rating on the stock.
Separately, Clarus Securities dropped their price target on HLS Therapeutics from C$33.00 to C$26.50 in a research report on Wednesday.
Shares of HLTRF stock opened at $10.96 on Thursday. The stock has a fifty day moving average of $11.58 and a two-hundred day moving average of $12.38. HLS Therapeutics has a 1 year low of $10.40 and a 1 year high of $16.44.
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
- Get a free copy of the StockNews.com research report on HLS Therapeutics (HLTRF)
- Facebook (NASDAQ: FB) Soars And Wall Street Delights
- Automatic Data Processing Is Ready To Scale New Heights
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.